Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study

II Gmizic, A Barac, N Todorovic, M Sabanovic… - The Journal of Infection …, 2024 - jidc.org
Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …
相关文章

Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study

II Gmizic, A Barac, N Todorovic, M Sabanovic… - The Journal of Infection …, 2024 - jidc.org
Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …

Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study.

II Gmizic, A Barac, N Todorovic… - Journal of Infection in …, 2024 - europepmc.org
Results The study was conducted between 15 December 2021 and 15 February 2022 and
included 320 patients. Of these, 165 (51.6%) received treatment with molnupiravir. The study …
[PDF] researchgate.net

[PDF][PDF] Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study

II Gmizic, A Barac, N Todorovic, M Sabanovic, N Kekic… - 2024 - researchgate.net
Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …

Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study

II Gmizic, A Barac, N Todorovic… - Journal of infection …, 2024 - pubmed.ncbi.nlm.nih.gov
Introduction The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …